--- title: "Recursion Pharmaceuticals | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 6.472 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285356809.md" datetime: "2026-05-06T10:34:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285356809.md) - [en](https://longbridge.com/en/news/285356809.md) - [zh-HK](https://longbridge.com/zh-HK/news/285356809.md) --- # Recursion Pharmaceuticals | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 6.472 M Revenue: As of FY2026 Q1, the actual value is USD 6.472 M, missing the estimate of USD 15.78 M. EPS: As of FY2026 Q1, the actual value is USD -0.22, beating the estimate of USD -0.255. #### Revenue Total revenue for Recursion Pharmaceuticals, Inc. was $6.5 million for the first quarter of 2026, a decrease compared to $14.7 million for the first quarter of 2025. Operating revenue was $6.3 million in Q1 2026, down from $14.8 million in Q1 2025. Grant revenue was $0.2 million in Q1 2026, compared to -$0.1 million in Q1 2025. #### Operating Costs and Expenses Total operating costs and expenses decreased to $135.0 million in Q1 2026 from $206.1 million in Q1 2025. Research and development expenses decreased to $87.9 million for the first quarter of 2026, from $129.6 million for the first quarter of 2025, which included $27.1 million in non-cash expenses in Q1 2025. General and administrative expenses were $34.6 million for the first quarter of 2026, a decrease from $54.7 million for the first quarter of 2025. Cost of revenue was $12.5 million in Q1 2026, down from $21.8 million in Q1 2025. #### Profitability Loss from operations was -$128.5 million in Q1 2026, an improvement from -$191.4 million in Q1 2025. Other income, net was $6.4 million in Q1 2026, compared to -$11.3 million in Q1 2025. Loss before income tax benefit was -$122.1 million in Q1 2026, compared to -$202.6 million in Q1 2025. Income tax benefit was $4.6 million in Q1 2026, up from $0.2 million in Q1 2025. Net loss was -$117.5 million for the first quarter of 2026, compared to a net loss of -$202.5 million for the first quarter of 2025. #### Cash Flow Net cash used in operating activities was -$81.1 million for the three months ended March 31, 2026, an improvement from -$132.0 million for the three months ended March 31, 2025. Net cash used in investing activities was -$0.3 million in Q1 2026, compared to -$7.3 million in Q1 2025. Net cash provided by (used in) financing activities was -$3.5 million in Q1 2026, compared to $40.5 million in Q1 2025. #### Cash Position Cash, cash equivalents and restricted cash for Recursion Pharmaceuticals, Inc. were $665.2 million as of March 31, 2026, compared to $753.9 million as of December 31, 2025. #### Unique Metrics Cash operating expense (non-GAAP), excluding partnership inflows and transaction costs, was $85.1 million for the three months ended March 31, 2026, compared to $120.2 million for the three months ended March 31, 2025. Recursion Pharmaceuticals, Inc. achieved a 30% reduction in year-over-year cash operating expenses, amounting to $85 million in Q1 2026. The company has generated over $500 million in partner inflows and delivered more than 10 milestones. A specific partnership highlight includes the acceptance of the 5th Sanofi milestone, resulting in $4 million for a lead series in a potential first-in-class oncology program. #### Outlook / Guidance Recursion Pharmaceuticals, Inc. reiterates its 2026 guidance of less than $390 million in operational cash burn, supporting a cash runway into early 2028 without additional financing. The company anticipates a regulatory update and additional clinical data for REC-4881 in the second half of 2026, along with additional Phase 1 dose escalation data for REC-1245 in the same period. Furthermore, data-driven go/no-go decisions on Phase 1 initiation for REC-7735 and REC-102 are expected in the second half of 2026, with early safety and PK data for REC-4539, REC-617, and REC-3565 anticipated in 2027. ### Related Stocks - [RXRX.US](https://longbridge.com/en/quote/RXRX.US.md) ## Related News & Research - [Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages](https://longbridge.com/en/news/272181644.md) - [Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here?](https://longbridge.com/en/news/270733155.md) - [Faron Pharmaceuticals LTD: Holding(s) In Company](https://longbridge.com/en/news/286725255.md) - [PMV Pharmaceuticals (NASDAQ:PMVP) Will Have To Spend Its Cash Wisely](https://longbridge.com/en/news/286912396.md) - [Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA | HNSA Stock News](https://longbridge.com/en/news/286864132.md)